Claims for Patent: 4,301,146

Summary for Patent: 4,301,146

Title:	Stabilization of 16-oxygenated prostanoic acid derivatives
Abstract:	A stable solid dosage form of the compound .+-.methyl(7-[3(.alpha.)-hydroxy-2-.beta.-(4(RS)-4-hydroxy-4-methyl-trans- 1-octen-1-yl)-oxycyclopent-1.alpha.-yl]heptanoate, said solid dosage form comprising from about 50 to about 500 parts of a polymer selected from the group consisting of hydroxypropylmethyl cellulose and polyvinylpyrolidone per part of said compound.
Inventor(s):	Sanvordeker; Dilip R. (Elk Grove Village, IL)
Assignee:	G. D. Searle & Co. (Skokie, IL)
Application Number:	06/173,292
Patent Claims:	1. A stable solid dispersion of the compound .+-.methyl(7-[3(.alpha.)-hydroxy-2-.beta.-(4(RS)-4-hydroxy-4-methyl-trans- 1-octen-1-yl)-oxycyclopent-1.alpha.-yl]heptanoate, said solid dispersion comprising from about 50 to about 500 parts of a polymer selected from the group consisting of hydroxypropylmethyl cellulose and polyvinylpyrolidone per part of said compound. 2. A dispersion of claim 1 additionally comprising a filler selected from the group consisting of microcrystalline cellulose, mannitol and lactose. 3. A dispersion of claim 2 wherein up to 1000 parts of filler per part of drug is employed. 4. A solid dispersion of claim 1 wherein said polymer is hydroxypropylmethyl cellulose. 5. A solid dispersion of claim 2 or 4 wherein said polymer is hydroxypropylmethyl cellulose and said filler is microcrystalline cellulose. 6. a solid dispersion of claim 2 or 4 wherein said polymer is hydroxypropylmethyl cellulose and said filler is mannitol. 7. A solid dosage form of claim 1 or 2 wherein said polymer is polyvinylpyrrolidone. 8. A solid dispersion of claim 2 or 4 wherein said polymer is polyvinylpropylene and said filler is microcrystalline cellulose. 9. A solid dispersion of claim 2 or 4 wherein said polymer is polyvinylpyrrolidone and said filler is mannitol. 10. A stable solid dosage form of the compound .+-.methyl-(7-[3(.alpha.)-hydroxy-2.beta.-(4(RS)-4-hydroxy-4-methyl-trans- 1-octen-1-yl)oxycyclopent-1.alpha.-yl]hept-4-cis-enoate, said solid dosage form comprising from about 50 to about 500 parts of a polymer selected from the group consisting of hydroxypropylmethyl cellulose and polyvinylpyrrolidone per part of said compound. 11. A dosage form of claim 10 additionally comprising a filler selected from the group consisting of microcrystalline cellulose, mannitol and lactose. 12. A dosage form of claim 11 wherein up to 1000 parts of filler per part of drug is employed. 13. A solid dosage form of claim 10 wherein said polymer is hydroxypropylmethyl cellulose. 14. A solid dosage form of claim 11 or 13 wherein said polymer is hydroxypropylmethyl cellulose and said filler is microcrystalline cellulose. 15. A solid dosage form of claim 11 or 13 wherein said polymer is hydroxypropylmethyl cellulose and said filler is mannitol. 16. A solid dosage form of claim 10 or 11 wherein said polymer is polyvinylpyrrolidone. 17. A solid dosage form of claim 11 or 13 or wherein said polymer is polyvinylpyrrolidone and said filler is microcrystalline cellulose. 18. A solid dosage form of claim 11 or 13 wherein said polymer is polyvinylpyrrolidone and said filler is mannitol. 19. A solid dosage form of claim 11 or 13 wherein said polymer is polyvinylpyrrolidone and said filler is lactose. 20. A solid dosage form of claim 11 or 13 wherein said polymer is hydroxypropylmethyl cellulose and said filler is lactose. 21. A solid dosage form of claim 2 or 4 wherein said polymer is hydroxypropylmethyl cellulose and said filler is lactose. 22. A solid dosage form of claim 2 or 4 wherein said polymer is polyvinylpyrrolidine and said filler is lactose.